兴齐眼药：39个产品继续纳入国家医保药品目录

Core Viewpoint - The company, Xingqi Eye Pharmaceutical, announced that 39 of its products will continue to be included in the National Medical Insurance Drug List, with no products being removed [1] Group 1: Product Inclusion - The 39 products consist of 8 Class A and 31 Class B drugs [1] - Notable products such as Cyclosporine Eye Drops (II), Compound Electrolyte Eye Irrigation Solution, and Sodium Hyaluronate Eye Drops remain in the National Medical Insurance Directory [1] Group 2: Future Implications - The new version of the National Medical Insurance Drug List will take effect on January 1, 2026 [1] - The short-term impact on the company's operating performance is expected to be minor [1] - Future sales of the drugs may be influenced by changes in pharmaceutical industry policies and market conditions, indicating uncertainty [1]